



FOR IMMEDIATE RELEASE

Tokyo, September 24, 2024

JT's License Partner LEO Pharma Announced FDA Acceptance of New Drug Application for Delgocitinib Cream, a Topical JAK Inhibitor

Japan Tobacco Inc. (JT) (TSE:2914) today announced that LEO Pharma A/S (LEO Pharma) issued a statement that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for delgocitinib cream, a topical Janus kinase (JAK) Inhibitor, for the treatment of adult patients with moderate-to-severe chronic hand eczema (CHE) on September 23, 2024.

About Delgocitinib

Delgocitinib is a non-steroidal, pan-JAK inhibitor that is expected to improve autoimmune and allergic diseases by inhibiting the action of JAKs, which play key roles in immune activation signaling in cells, by suppressing the overactivation of immune responses.

Delgocitinib was originated by JT. In 2014, JT and LEO Pharma entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan.

Torii Pharmaceutical Co., Ltd. distributes delgocitinib under the brand name CORECTIM[®] in Japan, where CORECTIM[®] Ointment 0.5% and CORECTIM[®] Ointment 0.25% are approved for the treatment of atopic dermatitis.

About Chronic Hand Eczema

Chronic hand eczema (CHE) is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.

###

Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand.

Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its "Fulfilling Moment, Enriching Life" purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit <https://www.jt.com/>.

Contact: Yunosuke Miyata, Director
Investor and Media Relations Division
Japan Tobacco Inc.
Tokyo: +81-3-6636-2914
E-mail: jt.media.relations@jt.com